POLish Bifurcation Optimal treatment Strategy randomized Study (POLBOSS) - Interim analysis

Transcription

1 POLish Bifurcation Optimal treatment Strategy randomized Study (POLBOSS) - Interim analysis Robert J. Gil 1,2, MD, PhD, FESC 1- Mossakowski Medical Research Centre, Polish Academy of Sciences 2- Invasive Cardiology Dept., Central Hospital of the Internal Affairs Ministry, Warsaw, Poland

2 Disclosures I have the following financial relationships to disclose: Consultancy: Balton, PL Official Research Grant Sponsored by Polish Ministry of Science and Higher Education N

3 BiOSS (Balton, PL) Delivery system is based on dedicated balloon (Bottle, Balton, PL) which restore MV MB sizes without need of additional dilatation (kissing like effect) It`s profile is quite low (1.08mm), which makes possible to implant stent even through 5 Fr guiding catheter Two parts of stent (dedicated for MV and MB) made of 316L stainless steel are connected with two struts at the step-up mid zone it keeps SB ostial diameter Balloon mid-marker allows exact stent positioning

4 BiOSS (Balton, PL) The stent construction prevents carina displacement, as a basic mechanism of side branch compromise The stent strut/vessel area ratio varies between 15 18%. Nominal foreshortening of the stent is less than 0.5%. Stent belongs to DES class biodegradable polimer (polilactide and polyglicolyc) with syrolimus (BiOSS Lim)

5 How BiOSS works? BiOSS after balloon deflation, copies the bifurcation configuration matching proximal distal main vessel size requirements. It fits all parts of bifurcation (parent vessel daughter branches) according to principles of optimality of energy distribution in coronary artery branching region (Murray law).

6

7 BiOSS vs regular DES Intravascular Ultrasound Study DES BiOSS p pre post pre post pre post MLA target [mm 2 ] 2.87± ± ± ± LA PL [mm 2 ] 4.78± ± ± ± LA DL [mm 2 ] 5.21± ± ± ± LA window [mm 2 ] 4.86± ± ± ± Window length (mm) 2.31± ± ± ± Gil RJ.: BiOSS vs DES mechanisms of lumen enlargement (under preparation)

8

9 POLish Bifurcation Optimal treatment Strategy randomized Study (POLBOSS) All bifurcation lesions (true and false) requires stenting Inclusion criteria Main branch >2.5mm Side branch >2.0mm Exclusion criteria Infarct-related artery Reference image acquisition (after intracoronary nitrate) Initial i.c. ECG from SB and MB First randomization Second randomization Only for branches w/o predilatation BiOSS Any DES SB protection No SB protection SB protection No SB protection 3rd randomization, only for DES group Bottle postdilatation ± SB balloon KBI No KBI

10 Study design Non-inferiority study Assumed TLR 6-10% Margin of Error 2% Loss of pts - 5% Planned population 360 pts (180 per group)

11 safety and feasibility study Primary end-point MACE event rates at 12 months Secondary end-points Device performance implantation failure rates Periprocedural safety rate of periprocedural SB compromise (SB closure rates, elev. CK-MB) Angiographic (after 9 months): Late Lumen Loss (LL) Percent Diameter Stenosis (%DS) Binary restenosis rate

12 BiOSS Lim Registry (FIM Study) Implantation protocol Wiring both branches MV predilatation (B/A ratio = ) SB predilatation according to operator decision BiOSS implantation atm at least 20 sec! Stent postdilatation Bottle balloon SB postdilatation if SB ostial %DS >70% (operator decision, not mandatory per protocol) KBI not required! IVUS recommended for all LM cases

13 Centres participating in POLBOS Study CSK MSWiA, Warsaw, Poland Robert J. Gil (PI) WSS, Olsztyn, Poland - Adam Kern KKKCW UMK, Bydgoszcz, Poland - Radoslaw Formuszewicz KKI USK, Bialystok, Poland - Slawomir Dobrzycki

14 Clinical characteristics

15

16

17

18

19 RESULTS 210 pts, 4 high volume (>1500 PCIs/year) centers 210 bifurcation lesions (210 patients) 97 BiOSS Expert (100% success rate) 117 DES stents (1 impl. failure)

20

21

22

23

24 Conclusions Interim analysis has showed that dedicated paclitaxel eluting bifurcation stent provides satisfactory results which seem to demonstrate equivalence in hard end points (death, MI, strokes). The completion of the POLBOS Study will show possible differences (or equivalence) of secondary end-points.

25

26

27

28 Thank you for attention!